Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWelly, Seisilya-
dc.description.abstractThe current treatments for Peripheral Artery Disease (PAD) generally lead to restenosis at the site of intervention, with only 33% of the patients have a patent artery one year after procedure. The use of anti-proliferative drugs, such as Paclitaxel (PTX) and Sirolimus, have been demonstrated to be successful in the treatment of restenosis in the coronary artery. However, limited success was reflected in the case of PAD. This is due to the higher probability of calcification and longer area of blockage in the peripheral artery as compared to that in the coronary artery. Being inspired by the properties of liposomes as a drug delivery carrier to release therapeutic agents sustainably, this project aims to encapsulate PTX and Sirolimus in liposomes to prevent restenosis after angioplasty procedure in PAD. Two types of lipids, namely egg phosphatidylcholine (EPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) were used to encapsulate 5 mole % of PTX. In vitro release from both formulations, as well as their liposomes size and encapsulated drug stability over the time, were characterized. Results show that PTX could be released sustainably, with negligible burst release. However, EPC formulation possessed faster release characteristics compared to POPC formulation. The encapsulated PTX in both formulations was stable at 4 oC throughout the study. As for liposomes size, POPC formulation was much more stable as compared to EPC formulation. For Sirolimus, 7.6 mole % of Sirolimus was loaded into EPC liposome and in vitro release, size and drug stability were determined. In vitro release of Sirolimus showed 30% of burst release at the first 3 hour, followed by sustained releasing of the drug in the next 28 days. Sirolimus formulation shows better drug and size stability while stored in 4 oC than that in 37 oC. In conclusion, PTX and Sirolimus have been successfully encapsulated into liposomes and sustained release of both drugs were achieved. All the formulations demonstrated good stability in terms of liposomes size and drug stability at 4 oC for at least one month. These formulations would be useful in reducing restenosis and their efficacy will be determined in vivo in the future study.en_US
dc.format.extent50 p.en_US
dc.rightsNanyang Technological University-
dc.titleFormulation and in vitro release study of drug loaded liposomes for peripheral artery diseaseen_US
dc.typeFinal Year Project (FYP)en_US
dc.contributor.supervisorSubramanian Venkatramanen_US
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.description.degreeBachelor of Engineering (Materials Engineering)en_US
item.fulltextWith Fulltext-
Appears in Collections:MSE Student Reports (FYP/IA/PA/PI)
Files in This Item:
File Description SizeFormat 
Welly Seisilya (U1221141E) - Final Submission FINAL.pdf
  Restricted Access
1.22 MBAdobe PDFView/Open

Page view(s)

Updated on Jul 27, 2021

Download(s) 50

Updated on Jul 27, 2021

Google ScholarTM


Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.